IMMUNOCORE LTD
BiotechIMMUNOCORE LTD is a biotechnology company focused on Oncology, Metabolic, Infectious Disease.
FDA Novel Drug Designations
(2022)See 1 novel approval →
IMMUNOCORE LTD's Key Drugs
IMMUNOCORE LTD's core commercial portfolio centers on KIMMTRAK, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
IMMUNOCORE LTD's Recent FDA Approvals
New NDA/BLA approvals for IMMUNOCORE LTD over the last two years — novel drugs only, excluding generics and label supplements.
IMMUNOCORE LTD's Therapeutic Areas
IMMUNOCORE LTD's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IMMUNOCORE LTD's Top Competitors
IMMUNOCORE LTD's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IMMUNOCORE LTD Pipeline Snapshot
IMMUNOCORE LTD has 14 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 2 Phase 2 and 10 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • KIMMTRAK leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/2 completed
- • Speed: 78 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2022-01-25
- Latest
- 2024-06-27
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges